Proof of Concept Presented at HUPO Integrates SLIM Innovation with Thermo Scientific Orbitrap Exploris 480 Mass Spectrometer to Supply Significant Signal Enhancement
CHADDS FORD, Pa., Jan. 11, 2023/ PRNewswire/– MOBILion Systems, Inc., a life science tools and instrumentation business, presented at the Human Proteome Company (HUPO) World Congress the very first of its kind proof of idea integrating their SLIM (structures for lossless ion adjustment) innovation with the Thermo Scientific ™ Orbitrap Exploris ™ 480 mass spectrometer.
A task including MOBILion and Thermo Fisher objectives to address the market’s current limitations in sensitivity, including obstacles in finding low abundance analytes. In a co-authored discussion at the HUPO 2022 World Congress in Cancún, Mexico last month, the research study teams demonstrated using SLIM innovation to improve signal intensities on the Orbitrap Exploris 480 mass spectrometer system approximately 200x. This signal boost was shown for low abundance peptide signals normally observed in proteomic workflows. The capability to reliably find and recognize peptides and proteins from single separated cells represents the next frontier in proteomics that necessitates an ultra-high sensitivity technological service. Additional details regarding this evidence of concept can be seen here.
We are excited about the debut of this 2nd model of SLIM technology to advance separation science.
Tweet this
MOBILion is proving its SLIM technology is a platform technology well-suited for modification, allowing it to be tuned to a variety of mass spectrometer platforms. In this latest model, MOBILion created the SLIM prototype to split ions into packets that are fed into the Orbitrap in an uniquely customizable manner in which just the SLIM innovation can achieve, increasing the sensitivity to catch more low abundance proteins and eventually increase the variety of proteoforms identified per experiment. In 2021, MOBILion presented its first SLIM-based commercial item, MOBIE ®, an outcome of its partnership with Agilent Technologies. MOBIE ® was designed to provide quick, effective, highly reproducible High Resolution Ion Mobility (HRIM) separations to separate and identify molecules that traditional liquid chromatography either stops working to separate, or need excessively long separation workflows. The instrument speeds up and streamlines workflows for a variety of analyte classes, consisting of peptides, proteins, lipids and glycans, with analysis that is 5 to 60 times quicker and substantially more reproducible than standard separation approaches.
“We are excited about the launching of this second model of SLIM innovation as another demonstration of how we have the ability to advance separation science. The early feedback from KOLs following the proof of idea combination with the Orbitrap platform has actually been extremely favorable. We are eagerly anticipating continuing to work with Thermo Fisher to advance the concept even further and enhance the efficiency of the Orbitrap platform of mass spectrometers,” states Dr. Melissa Sherman, CEO of MOBILion Systems Inc.To discover more about MOBILion Systems and its separations innovation, including MOBIE ®, go to www.mobilionsystems.com. About MOBILion SystemsInc. is advancing separation science and unraveling complex analyses with the commercialization of products based on Structures for Lossless Ion Adjustment( SLIM)platform technology. MOBILion’s items supply deeper level characterization than what is possible with incumbent techniques, revealing what others leave unseen. When integrated with mass spectrometry, MOBILion’s separation innovation provides higher resolution, much faster and more reproducible analysis to expose molecules most important in defining biologic therapies, finding biomarkers, enhancing the accuracy of diagnostics tests, and guaranteeing food and environmental security. Processing population-scale samples in weeks versus years and discovering particles other instruments miss out on, make treatments more secure and more efficient, accelerate illness prediction and medical diagnosis, and boost the development of brand-new treatments. The business is headquartered in Chadds Ford, Pennsylvania within the Philadelphia biopharmaceutical and medical development passage. Get in touch with us on LinkedIn or check out www.mobilionsystems.com SOURCE MOBILion Systems